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Corticotropin-releasing hormone and extracellular
mitochondria augment IgE-stimulated human
mast-cell vascular endothelial growth factor
release, which is inhibited by luteolin
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Abstract
Background: Autism spectrum disorders (ASDs) are neurodevelopmental disorders characterized by varying
degrees of dysfunctional social abilities, learning deficits, and stereotypic behaviors. Many patients with ASDs have
‘allergy-like’ symptoms and respond disproportionally to stress. We have previously shown that the peptide
neurotensin (NT) is increased in the serum of young children with autism and that can stimulate extracellular
secretion of mitochondrial (mt)DNA which was also increased in the serum of these children.
Methods: Human mast cells were stimulated by corticotropin-releasing hormone (CRH), mitochondrial DNA, IgE/anti-IgE,
either for 24 hours to measure vascular endothelial growth factor (VEGF) release by ELISA or for 6 hours or quantitative
PCR.
Results: CRH augmented IgE/anti-IgE-induced human mast-cell release of VEGF and it also induced the expression of IgE
receptor (FcεRI) on mast cells. Moreover, sonicated mitochondria also augmented VEGF release, and this effect was
blocked by the natural flavone luteolin.
Conclusion: These results indicate that stress and infection-mimicking extracellular mitochondrial components augment
allergic inflammation that may be involved in the early pathogenesis of ASDs. Moreover, luteolin inhibits these processes
and may be helpful in the treatment of ASDs.
Introduction
Autism spectrum disorders (ASDs) are pervasive devel-
opmental disorders for which no distinct pathogenesis,
biomarkers, or effective treatment have been identified.
ASDs involve some immune dysfunction in the patient
[1] or in the mother during gestation [2], and may
have a neuroimmune component [3]. Many children
with ASDs also have atopic features [4] or food aller-
gies [5-7] that present as ‘allergy-like’ symptoms [7,8].
Such symptoms often occur in the absence of increased
serum IgE levels or positive skin-prick tests, suggesting
mast-cell activation by non-immune triggers [9]. Increased
anxiety seems to be present in at least a subgroup of
patients with ASDs, who may also be more prone to stress
[10].
We previously showed that corticotropin-releasing hor-
mone (CRH), secreted under stress, could induce release
of vascular endothelial growth factor (VEGF) from human
mast cells [11]. We found that the neuropeptide neuroten-
sin (NT), which is present in both the brain and gut, is sig-
nificantly increased in the serum of young children with
autism [12]. It is interesting that the distribution of NT
receptors is more concentrated in the brain Broca area
[13], which regulates speech, a function commonly lost in
children with autism [14]. We also found that the serum
of the same patients had higher levels of extracellular
mitochondrial (mt)DNA [15], and NT stimulated release
of extracellular mtDNA from human cultured mast cells
[15]. We also found that the natural flavonoid luteolin can
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inhibit the ability of IgE [16] and mercury [17] to induce
VEGF release from human mast cells.
In the current study, we investigated the effect of
CRH and mitochondria on VEGF release from IgE/
anti-IgE-stimulated human mast cells, the effect of
CRH on gene expression of the high affinity IgE re-
ceptor (FcεRI), and the effect of the flavone luteolin
on VEGF release.
Methods
The study was approved by the human institutional re-
view board of Tufts Medical Center (Boston, MA, USA)
under Exemption Number 4 for discarded samples with-
out any identifiers.
Culture of human mast cells
Human umbilical cord blood was collected from
mothers who had normal uncomplicated deliveries at
Tufts Medical Center. Human cord blood-derived cul-
tured mast cells (hCBMCs) were prepared using hemato-
poetic stem cells (CD34+) isolated by positive selection of
CD34+/AC133+ cells by magnetic cell sorting using an
AC133+ cell isolation kit (Milletnyi Biotec, Auburn, CA,
USA) as previously reported [18]. CD34+ cells were grown
in serum-free expansion medium (StemSpan; StemCell
Technologies, Vancouver, BC, Canada), supplemented
with 100 ng/ml recombinant human stem cell factor
(rhSCF; kindly supplied by Sweden Orphan Biovitrum AB,
Stockholm, Sweden), 100 U/ml penicillin, 100 μg/ml
streptomycin (Invitrogen, Carlsbad, CA, USA) and IL-3
(R&D Systems, Minneapolis, MN, USA) for the first
3 weeks, then in the serum-free expansion medium with
50 ng/ml IL-6 (Peprotech, Rocky Hill, NJ, USA) and for 8
to 10 weeks, with fetal bovine serum (Invitrogen/Gibco,
Carlsbad, CA, USA) added from week 6. The purity of the
hCBMCs was evaluated by immunocytochemical staining
for tryptase [18]. hCBMCs cultured for 7 to 10 weeks were
used for the experiments.
LAD2 cells (kindly supplied by Dr A.S. Kirshenbaum,
National Institutes of Health, NIH, USA), derived from a
human mast-cell leukemia cell line, were cultured in
serum-free medium medium (StemProW-34; Invitrogen)
supplemented with 100 U/ml penicillin/streptomycin
and 100 ng/ml rhSCF (Sweden Orphan Biovitrum AB,
Sweden).
Mitochondrial preparation
A commercial kit (Mitochondria Isolation Kit for Cells;
Pierce Scientific, Rockford, IL, USA) was used to isolate
mitochondria from cultured mast cells. Mitochondria were
isolated under sterile conditions at 4°C in accordance with
the manufacturer’s instructions, and then subjected to
sonication for 2 minutes at 4°C to release all inner compo-
nents. The mtDNA and protein concentrations were
determined by UV spectrophometry (NanoDrop 2000;
Thermo Scientific, Waltham, MA, USA). The purity of the
mitochondrial fraction was confirmed by the absence of gly-
ceraldehyde 3-phosphate dehydrogenase (GAPDH) and lac-
tate dehydrogenase (markers of microsomal contamination)
and of 5′ nucleotidase and glucose-6-phosphatase (markers
of cytoplasmic contamination).
Vascular endothelial growth factor release assay
VEGF secretion measured from LAD2 cells after pre-
treatment with CRH (10 μmol/l) for 24 hours, followed
by 2 hours of incubation with IgE (1 microgram/μl) in
response to anti-IgE (10 microgram/μl). Human mast
cells were treated with IgE (1 μg/ml) for 2 hours (Mill-
pore, MA, USA), then washed, and luteolin (100 μmol/l)
was added for 30 minutes before stimulation with mito-
chondria (0.1 and 10 microgram/μl) and anti-IgE (10 μg/
ml) (Dako, Carlsbad CA, USA). VEGF release was mea-
sured by ELISA (R&D systems, Minneapolis, MN, USA)
in the supernatant taken from control and stimulated
hCBMC cultures.
Quantitative PCR
Total RNA from cultured mast cells and human skin biop-
sies was isolated using a commercial kit (RNeasy Mini Kit;
Qiagen, Valencia, CA, USA) and reagent (Trizol; Invitrogen)
respectively, in accordance with the manufacturer’s instruc-
tions. Reverse transcription was performed with 300 ng of
total RNA using the iScript cDNA synthesis kit (BIO-RAD,
Hercules, CA). To measure FcεRI expression, cells were
incubated for 6 hours with CRH (Sigma-Aldrich, MA,
USA) and quantitative PCR was performed using Taqman
gene expression assays (Applied Biosystems, Foster City,
CA, USA). Samples were run at 45 cycles using a real-time
PCR system (7300; Applied Biosystems). Relative mRNA
abundance was determined from standard curves run
with each experiment. mRNA gene expressions were
normalized to GAPDH endogenous control. (Hu, VIC
TAMRA; Applied Biosystems)
Statistical analysis
All experiments were performed in triplicate (n = 3) and
repeated (n = 5). Results are presented as mean ± SD.
Data from stimulated and control samples were com-
pared using the unpaired two-tailed, Student’s t-test.
p< 0.05 was considered significant.
Results
Because many children with autism have allergic symp-
toms are more anxious and over-react to stress, we
investigated if CRH would affect allergic mast-cell activa-
tion. Addition of CRH (10 μmol/l) together with or after
anti-IgE had no effect on anti-IgE-induced VEGF release
(results not shown). Pretreatment of LAD2 cells for 24
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hours with CRH (10 μmol/l) followed by 2 hours of incu-
bation with IgE augmented VEGF release in response to
anti-IgE (Figure 1A). The amount of CRH required was
high because LAD2 cells do not express many CRH
receptors.
We then investigated if such augmentation might be due
to increase in FcεRI gene expression. Incubation of
hCBMCs with CRH (0.1, 1, 10 μmol/l) for 6 hours
increased FcεRI gene expression by almost five-fold
(Figure 1B). Incubation of mast cells with CRH (10 μmol/l)
for 48 hours increased FcεRI gene expression by almost
200-fold (results not shown).
We then investigated the effect of mitochondria. Treat-
ment of hCBMCs with sonicated mitochondria (0.1 and 10
microgram/μl) stimulated some VEGF release (Figure 2),
but addition of mitochondria to anti-IgE-stimulated mast
cells significantly increased VEGF release (Figure 2). Pre-
treatment with luteolin (100 μmol/l) for 30 minutes
completely inhibited the VEGF release induced by mito-
chondria and anti-IgE, and even caused it to drop below
basal levels (Figure 2).
Discussion
In this report, we show that CRH not only can augment
allergic mast-cell release of VEGF, but can also induce
FcεRI expression in these human mast cells. Our finding
is specific, because the peptide substance P had been
shown previously to decrease FcεRI gene expression [19],
as also does lipopolysaccharide [20]. These results could
explain how stress may worsen allergy-like symptoms in
patients with ASDs [6,8,21]. It has previously been
shown that CRH can augment NT-induced VEGF release
[22]. Hence, CRH might augment both allergic and non-
immune mast-cell activation. The mechanism of such
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Figure 1 CRH augments VEGF release from IgE/anti-IgE-stimulated human mast cells, and increases FcεRI gene expression. (A) VEGF
secretion from LAD2 cells was measured after pretreatment with CRH 10 μmol/l for 24 hours, followed by 2 hours of incubation with IgE
1 microgram/μl in response to anti-IgE 10 μg/ml. (B) FcεRI mRNA expression was assessed after stimulation of hCBMCs with CRH (0.1, 1, 10 μmol/
l) for 6 hours. For all experiments, n = 5; *p< 0.05, **p< 0.01, ***p< 0.001 compared with control.
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Increased anxiety seems to be present in at least a sub-
group of patients with ASDs, who may also be more prone
to stress [10]. A comparison of 34 adults with autism and
20 controls, matched for age, gender, and intellectual ability,
found that patients with ASDs were three times as anxious
as controls, and were significantly less able to cope with
stress [23]. Acute stress can activate brain mast cells, an ef-
fect abolished by pretreatment with polyclonal antiserum to
CRH [24]. Subsequently, CRH was reported to activate
brain mast cells and increase blood–brain barrier per-
meability in rodents [25,26], particularly in brain areas
containing mast cells [27]. The direct effect of CRH was
documented by intradermal administration leading to
increased vascular permeability in rodents and humans,
through activation of CRHR-1 [28].
We also found that sonicated mitochondrial compo-
nents at (10 microgram/μl) stimulates VEGF release,
which also augments allergic stimulation of VEGF release
from human mast cells. At the present, we are not sure
which mitochondrial components are responsible for
VEGF release. They may include ATP, mtDNA, or formyl
peptides found in mitochondria. VEGF is also known to
stimulate mitochondrial biogenesis [29], suggesting a pos-
sible paracrine effect on secreted VEGF on the mitochon-
dria of neighboring cells.
Several studies have reported mitochondrial dysfunc-
tion in autism [30], which may involved a subset of chil-
dren with autism [31,32]. Mitochondria are the primary
energy-generating organelles in eukaryotic cells, and
they participate in multiple intracellular processes, in-
cluding calcium buffering [33]. However, mitochondria
were originally bacteria that became symbiotic with
eukaryotic cells, and are typically prevented from being
released extracellularly by autophagy [34]. We previously
found increased extracellular mtDNA in the serum of
young children with autism [15]. The present results indi-
cate that extracellular mitochondria components can aug-
ment allergic mast-cell stimulation. This action may be in
addition to any direct effect that mitochondrial components
may have on the immune system. For instance, damage-
associated mitochondrial pattern are able to activate Toll-
like receptor 9 on human peripheral polymorphonuclear
leukocytes, leading to release of interleukin-8 [35].
Given that ASDs has been associated with brain inflam-
mation and oxidative stress [1,3,36], we investigated the ef-
fect of the flavone luteolin, which has anti-inflammatory
and anti-oxidant properties [37]. We found that luteolin
100 μmol/l was able to inhibit the augmenting effect at
mitochondria on allergic human mast-cell activation. We
used this concentration because it had been previously
shown to cause maximal inhibition of mast cells and
mast-cell-dependent stimulation of activated T cells [16].
Luteolin also blocks methyl mercury-induced VEGF release
from human mast cells [17]. Myricetin, the structural ana-
log of luteolin, can also inhibit mast-cell activation [38],
and methyl mercury-induced mitochondrial dysfunction
[39]. Luteolin also blocks activated peripheral blood mono-
nuclear cells from patients with the inflammatory brain
disease multiple sclerosis [40]. A new luteolin-containing
dietary supplement was recently shown to have significant
benefit in children with ASDs [41]. Luteolin may therefore
be useful for the treatment of brain inflammation [40,42].
Conclusion
Augmentation of allergic and mitochondria-stimulated
mast-cell activation by CRH secreted by stress may ex-
plain at least some of the symptoms of patients with
Figure 2 Mitochondria augment VEGF release from IgE/anti-IgE-stimulated human mast cells, and inhibition by luteolin. (A) VEGF
secretion from hCBMCs was measured after pretreatment with IgE 1 microgram/μl for 2 hours and then incubating with mitochondria
(0.1 and 10 microgram/μl) and anti-IgE (10 microgram/μl) for 24 hours. Pretreatment with luteolin 100 μmol/l for 30 minutes completely inhibited
VEGF release and dropped it even below basal levels. For all experiments, n = 5; *p< 0.05, **p< 0.01, ***p< 0.001 compared with control.
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ASDs [43,44]. Other environmental triggers may also
contribute ASDs [45,46], and to ‘mast-cell activation syn-
drome’ [47]. Luteolin may provide some degree of pro-
tection against these.
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